Navigation Links
Major breakthrough in the treatment of cancers and infectious diseases

Montreal researchers identify new anti-cancer, anti-infection response control mechanism

Dr. André Veillette, a researcher at the Institut de recherches cliniques de Montréal (IRCM), and his team will publish in the upcoming issue of the prestigious journal Nature Immunology of Nature Publishing Group, a discovery that could significantly advance the treatment of cancers and infectious diseases. Current treatments frequently achieve only limited results with these types of diseases, which affect hundreds of thousands of Canadians.

Dr. Veillette's team identified one of the basic mechanisms controlling NK ("natural killer") cell activity. Produced by the immune system, NK cells are responsible for recognizing and killing cancer cells and cells infected by viruses such as the viruses causing hepatitis and herpes. NK cell deficiency is associated with a higher frequency of cancers and serious infections. Dr. Veillette's breakthrough demonstrates that a molecule known as EAT-2, present in NK cells, suppresses its killer function. Inhibiting EAT-2 with medications could boost NK cell activity, helping to combat cancers and infections.

This publication constitutes a significant milestone for Dr. Veillette, an internationally renowned expert in the identification of the molecular mechanisms controlling the immune system. The article, which is slated for publication online on August 28 in Nature Immunology, gives genetic evidence for the inhibiting role of EAT-2 in NK cells. It is the product of over five years of intensive research by Dr. Veillette's team.

More specifically, by studying mice in which the EAT-2 protein is eliminated through genetic manipulations, Dr. Veillette's team has established that suppressing EAT-2 results in the production of NK cells that are much more effective at killing cancer cells. Inhibiting the function of EAT-2 with medications could therefore stimulate the killer function of NK cells, and increase their ca pacity to destroy cancer and virus-infected cells. These medications could be used in combination with chemotherapy and radiotherapy to improve the effectiveness of anti-cancer treatments. Teams around the world have been trying without success for many years to develop methods to increase NK cell activity. In this light, the discovery of Dr. Veillette's team opens new avenues for the treatment of cancers and communicable diseases.


'"/>

Source:Institut de recherches cliniques de Montreal


Related biology news :

1. Major new UNC-based drinking water study suggests pregnancy fears may be overstated
2. Major advance made on DNA structure
3. Major WHO study concludes calcium supplements can reduce complications during pregnancy
4. Major obesity gene is lost in the shuffle
5. Major initiative proposed to address amphibian crisis
6. Major cancer study aims to identify protein markers for early-stage disease
7. Major link in brain-obesity puzzle found
8. Major gene study uncovers secrets of leukemia
9. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
10. MUHC researchers make cancer target breakthrough
11. Researchers report breakthrough against world’s deadliest viruses
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... , ... February 21, 2017 , ... ... organizations to build connected digital health applications, announced a partnership with Redox, a ... to seamlessly connect to many clinical systems while keeping data secure in the ...
(Date:2/21/2017)... (PRWEB) , ... February 21, ... ... the Life -Sciences division, Treximo will pair its $200M operational capacity with ... consulting and project management in areas affecting quality and operational management. ...
(Date:2/21/2017)... NEW YORK , Feb. 21, 2017   ... US, an international IT solutions and managed services provider ... offering – Service Desk for Epic. The new service ... their internal Epic resources by giving physicians, nurses and ... IT specialists for tier-one support. This will allow hospital ...
(Date:2/20/2017)... MONTREAL , Feb. 20, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... as President and CEO and Fabrice Orecchioni, the company,s COO, has ... as COO over the past four years, Fabrice has overseen the ... Sarnia and the management of the Mitsui JV.  Fabrice ... for the proposed China JV. ...
Breaking Biology Technology: